Comparison Of Dendritic Cell Differentiation Markers In Patient Suffering Leukemia With Normal Healthy One

Generating potent dendritic cells (DCs) in vaccination concept has been the focus of manyresearches and it is of great interest to produce desired mature DCs against tumor antigens of thepatients. To this end, maturity process must be performed efficiently. But in some situations andcases, monocytes derived from peripheral blood cells (PBMCs) might not express the maturitymarkers even in the presence of maturity induction materials like lipopoly saccharide. To comparethe maturity process between monocytes (MOs) derived from control and cancer bearing person,PBMCs of healthy and patient suffering leukemia were isolated and the flow cytometric data of bothsamples were compared. PBMCs were isolated using ficoll paque and after 2 hr adherence cellculture, the MOs received IL-4 and GMCSF for 5 days in complete RPMI supplemented with Lglutamine,non-essential acid amine, penicillin streptomycin and 10% fetal bovine serum. After thatLPS was added for 2 days. The markers of HLA-DR, CD86, and CD83 were checked on monocytes onfirst day, 5th day and 7th day in both normal one and the leukemia sample. The flow cytometricanalysis showed mean fluorescence intensity (MFI) of 97.1, 508 and 2908 in CD86, MFI of 55.3, 659and 727 in HLA-DR, MFI of 3.92, 51.1 and 126 in CD83 in normal person. While MFIs of these markersin the person undergone leukemia were 4.64, 23.6 and 279 in CD86, 26.4, 3.32 and 3.27 in HLA-DRand 2.56, 2.27 and 5.42 in CD83 respectively on 1st day, 5th day and 7th day in the presence of IL-4,GMCSF and LPS. Overall, maturity induction in MOs derived from patients suffering cancer forclinical use might not occur efficiently even in the presence of tumor antigens.